My laboratory investigates the origin, development and immune regulatory functions of myeloid cells in organ transplantation. As negative regulators of the immune response, myeloid cells represent a novel therapeutic approach to promote organ transplant acceptance. We have recently evaluated a targeted therapeutic delivery system in which drug-loaded nanoparticles that specifically target myeloid cells induce long-term allograft acceptance with minimal immunosuppressive drug usage. As this innovative approach combines existing FDA approved agents that target myeloid cells in vivo, the pre-clinical development of this technology has an immediate path to translation.